MilliporeSigma Collaborates with Angiex on Cancer Drug
MilliporeSigma announced a collaboration with Angiex, a biotechnology start-up, to support the development of Angiex’s lead oncology antibody drug candidate to clinical use.
On Aug. 29, 2017, MilliporeSigma announced a collaboration with Angiex, a biotechnology start-up based in Cambridge, MA, to support the development of TM4SF1, Angiex’s lead oncology antibody drug candidate, to clinical use. The treatment is an antibody-drug conjugate (ADC) therapy for cancer against a vascular target.
The collaboration is the first project to take place at MilliporeSigma’s biodevelopment center in Burlington, MA, set to open in October 2017. Angiex will be given end-to-end process development tools, education programs, and training by the company.
“Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs,” said Udit Batra, CEO at MilliporeSigma, in a company press release. “With an end-to-end approach, MilliporeSigma can facilitate and accelerate scaling and technical transfer for companies like Angiex.”
Angiex CEO Dr. Paul Jaminet added: “Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate MilliporeSigma’s expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors.”
Source: MilliporeSigma
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
